BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/26/2024 6:56:10 AM | Browse: 64 | Download: 320
 |
Received |
|
2024-04-25 14:19 |
|
Peer-Review Started |
|
2024-04-25 14:19 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-06-15 04:10 |
|
Revised |
|
2024-06-24 16:57 |
|
Second Decision |
|
2024-07-08 08:58 |
|
Accepted by Journal Editor-in-Chief |
|
2024-07-14 14:02 |
|
Accepted by Executive Editor-in-Chief |
|
2024-07-17 07:05 |
|
Articles in Press |
|
2024-07-17 07:05 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-07-19 03:57 |
|
Publish the Manuscript Online |
|
2024-07-26 06:56 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Systematic Reviews |
| Article Title |
Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Venkata Buddhavarapu, Gagandeep Dhillon, Harpreet Grewal, Pranjal Sharma, Rahul Kashyap and Salim Surani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Salim Surani, FACP, FCCP, MD, MHSc, Adjunct Professor, Department of Medicine & Pharmacology, Texas A&M University, 40 Bizzell Street, College Station, TX 77843, United States. srsurani@hotmail.com |
| Key Words |
Teplizumab; Diabetes mellitus type 1; Adverse effects; Monoclonal antibody; Systematic review |
| Core Tip |
Teplizumab is an anti-CD4 antibody that has been shown to delay the clinical onset of diabetes mellitus type 1. Our systematic review evaluates the incidence of total adverse effects and a systems-based risk reported in various clinical trials. Our review shows an increased incidence of adverse effects in patients receiving Teplizumab compared to placebo, but this risk is not statistically significant. There is also a statistically significant increased risk of gastrointestinal, dermatological, and hematological adverse effects in the Teplizumab group compared to placebo. More trials need to be conducted to understand better the risk of side effects related to Teplizumab. |
| Publish Date |
2024-07-26 06:56 |
| Citation |
<p>Buddhavarapu V, Dhillon G, Grewal H, Sharma P, Kashyap R, Surani S. Safety of teplizumab in patients with high-risk for diabetes mellitus type 1: A systematic review. <i>World J Diabetes</i> 2024; 15(8): 1793-1801</p> |
| URL |
https://www.wjgnet.com/1948-9358/full/v15/i8/1793.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v15.i8.1793 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
